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Expression of apoptosis-regulatory genes in lung tumour cell lines:
relationship to p53 expression and relevance to acquired drug resistance
JG Reeve, J Xiong, J Morgan and NM Bleehen
Medical Research Council Clinical Oncology and Radiotherapeutics Unit, Medical Research Council Centre, Cambridge CB2 2QH,
UK.
Summary As a first step towards elucidating the potential role(s) of bcl-2 and bcl-2-related genes in lung
tumorigenesis and therapeutic responsiveness, the expression of these genes has been examined in a panel of
lung cancer cell lines derived from untreated and treated patients, and in cell lines selected in vitro for
multidrug resistance. Bcl-2 was hyperexpressed in 15 of 16 small-cell lung cancer (SCLC) cell lines and two of
five non-small-cell lung cancer (NSCLC) lines compared with normal lung and brain, and hyperexpression was
not chemotherapy related. Bcl-x was hyperexpressed in the majority of SCLC and NSCLC cell lines as
compared with normal tissues, and all lung tumour lines preferentially expressed bcl-xl-mRNA, the splice
variant form that inhibits apoptosis. Bax gene transcripts were hyperexpressed in most SCLC and NSCLC cell
lines examined compared with normal adult tissues. Mutant p53 gene expression was detected in the majority
of the cell lines and no relationship between p53 gene expression and the expression of either bcl-2, bcl-x or bax
was observed. No changes in bcl-2, bcl-x and bax gene expression were observed in multidrug-resistant cell lines
compared with their drug-sensitive counterparts.
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Recent evidence suggests that the genetic regulation of
apoptosis involves a complex interplay between certain
oncogenes, p53, bcl-2 and bcl-2-related proteins, and that
subversion of this process, through mutation or altered
expression of these genes, is of fundamental importance
during tumorigenesis (McDonnell, 1993; Williams and Smith,
1993). Thus, mutation of the p53 tumour-suppressor gene,
which occurs frequently in tumours (Hollstein et al., 1991),
results in loss of p53 function in inducing apoptosis in a cell
type- and stimulus-specific manner. t(14:18) chromosomal
translocation resulting in the juxtaposition of the immuno-
globulin heavy-chain gene with the bcl-2 gene, which
functions in enhancing cell survival through its ability to
suppress apoptosis (for review see Reed, 1994), results in
transcriptional deregulation and abnormally high levels of
bcl-2 protein, and is a critical event in the molecular
pathogenesis of the majority of human B-cell follicular
lymphomas. In addition to lymphomas with the t(14:18)
translocation, high levels of bcl-2 protein and/or aberrant
patterns of bcl-2 protein production have been described in a
wide variety of human tumours, including many leukaemias,
neuroblastomas and other tumours of neural origin, and in
carcinomas of the lung, prostate, colon and nasopharynx
(Campos et al., 1993; Reed et al., 1991; McDonnell et al.,
1992; Pezzella et al., 1993; Lu et al., 1993). As there is little or
no evidence for gross alterations in bcl-2 gene structure in
these cancers, the frequent hyperexpression of bcl-2 in such
tumours may indicate the existence of other genetic
mechanisms for dysregulation of bcl-2 gene expression.
Interestingly, recent studies have shown that the wild-type
p53 tumour-suppressor gene product can inhibit bcl-2
expression through its interaction with a p53-dependent
negative response element in the bc1-2 gene (Miyashita et
al., 1994a,b). This raises the possibility that p53 gene
inactivation may account for the widespread hyperexpression
of bcl-2 in tumours. Although, at present, there are few data
on the expression in tumours of the bcl-2-related genes bcl-x
and bax, the roles played by these genes in the regulation of
apoptosis suggest their likely involvement in tumour
development. Bcl-x has been shown to be involved in both
positive and negative regulation of apoptosis (Boise et al.,
1993). Alternative splicing results in two distinct bcl-x mRNA
species, namely bcl-x, and bcl-x,. Whereas bcl-xl inhibits cell
death upon growth factor withdrawal, bcl-x, encodes a
protein that increases the dependence of cells on growth
factors to prevent cell death and, importantly, inhibits the
ability of bcl-2 to enhance the survival of growth factor-
deprived cells. Thus, bcl-x plays a major role in regulating the
dependence of cells on continuous exogenous signals to
prevent cell death, raising the possibility that altered
regulation of bcl-x expression or of mRNA splicing could
confer autonomous cell survival potential and contribute to
tumour development. In addition to bcl-xs, bcl-2 has been
shown to be modified in its function by bax, which
accelerates apoptosis (Oltvai et al., 1993). The bax gene
product heterodimerises with, and inactivates, bcl-2 protein,
and it has been suggested that the ratio of bax to bcl-2
determines survival or death following an apoptotic signal.
Importantly, bax gene expression has also been shown to be
regulated by wild-type p53 (Miyashita et al., 1994a), but
whereas p53 negatively regulates bcl-2 expression, it up-
regulates bax expression, suggesting that p53-induced
alterations in bcl-2 and bax expression play a major role in
p53-induced apoptosis. Although the effect of p53 inactiva-
tion on bax gene expression remains to be determined, it has
been predicted that a low level of bax expression will occur in
tumours showing p53 loss (Miyashita et al., 1994a). This, in
turn, might be expected to contribute indirectly to enhanced
survival in such tumours via the release of bcl-2 protein from
bax inhibition.
The intense interest in the genetic deregulation of
apoptosis arises not only from its role in oncogenesis but
also from the increasing realisation of the importance of
apoptosis as a mechanism of cell death by anti-cancer drugs,
radiation and other toxic pathways (Ohmori et al., 1993;
Walton et al., 1993; Miyashita and Reed, 1992; Manome et
al., 1993; Hennet et al., 1993). Importantly, bcl-2 gene
transfection has been shown to confer resistance to several
anti-cancer drugs by a mechanism that does not involve
classical drug resistance pathways such as drug transport or
topoisomerase II expression (Fisher et al., 1993; Kamesaki et
al., 1993). As p53 is required for the induction of apoptotic
death by y-irradiation and a variety of chemotherapeutic
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drugs (Lowe et al., 1993), its frequent inactivation in
tumours, together with deregulation of bcl-2 and possibly
bax expression, is likely to be a key determinant of cell
survival in response to a variety of cytotoxic insults. Hence,
knowledge of the expression of these genes, together with bel-
x, in tumour cells may provide a rational basis for novel
therapeutic strategies for the treatment of several types of
cancer.
As a first step towards investigating the possible
involvement of bcl-2, bcl-x, and bax in lung tumour
development and the roles played by these genes in
determining therapeutic responsiveness, the present study
investigates the expression of bcl-2, bcl-x and bax together
with p53 in small-cell lung cancer (SCLC) cell lines derived
from untreated and pretreated patients, in non-small-cell lung
cancer (NSCLC) cell lines and in SCLC and NSCLC cell
lines selected in vitro for multidrug resistance.
Materials and methods
Cells
With the exception of NCI-H69 (donated by Drs D Carney
and A Gazdar, National Cancer Institute Navy Medical
Oncology Branch, Bethesda, MD, USA) and LUDLU-1
(supplied by Dr P H Rabbitts of this unit), all lung tumour
cell lines used in this study were generous gifts from Dr P R
Twentyman (of this unit). The derivation and characterisa-
tion of the cell lines COR-L24, -L42, -L47,-L51, -L88 and -
L23, have been described previously (Baillie-Johnson et al.,
1985). COR-L96C, -1103, -L266, -L279, -L311, -L316 and -
L321 were similarly derived from pathologically confirmed
SCLC patients. Cell lines COR-L51, -L88, -L103, -L311, -
L316 and -L321 were derived from SCLC patients receiving
combination chemotherapy including etoposide, vincristine,
methotrexate and cycloheximide. The derivation and char-
acterisation of the multidrug-resistant variants of NCI-H69,
MOR and COR-L23 are described in detail elsewhere
(Twentyman et al., 1986). COR-L105 and MOR were
derived from a patient with a histological diagnosis of
adenocarcinoma of the lung. The cell line BEN was derived
from a squamous cell lung carcinoma. The B-cell lymphoma
cell line DoHH2 (Cotter et al., 1994) was generously supplied
by Dr FE Cotter, LRF Department of Haematology and
Oncology, Institute of Child Health, London, UK. All cell
lines were routinely grown in RPMI-1640 medium supple-
mented with 2 mM L-glutamine, 10% fetal calf serum (FCS),
10 ,ug ml-1 penicillin and 10 jug ml-' streptomycin (all Gibco
BRL, Paisley, UK) with the exception that DoHH2 was
grown in RPMI-1640 supplemented with 5% FCS.
Probes
A 2.7 kb bcl-2 cDNA probe (Cambridge Bioscience, Cam-
bridge, UK) and the 2.1 kb pProSp 53 cDNA (Matlashewski
et al., 1987) (kindly supplied by Dr PH Rabbitts) was used to
investigate bcl-2 and p53 gene expression respectively. To
investigate expression of the bax and bcl-x genes, cDNA
probes were generated by reverse transcriptase polymerase
chain reaction (RT-PCR) using RNA derived from normal
human tissue or from untransformed human cells. For RT-
PCR, 1 jig of mRNA was added to 1 jil of 0.4 jig jl-
random hexamer primers (Amersham International) and 5 jl
of 2 mM dNTP mixture (Pharmacia LKB, UK) in the
presence of 1 unit jl-' human placental ribonuclease
inhibitor (Amersham International), followed by denatura-
tion at 65°C for 5 min and annealing at 25°C for a further
5 min. The reaction was cooled on ice and 5 4ul of 2 mM
dNTP mixture was added together with 0.5 ,ul of super
reverse transcriptase (HT Biotechnology, Cambridge, UK) to
give a final volume of 20 ,ul. The mixture was incubated at
41°C for 1 h. First-strand cDNA (10 jdl) was added to 5 ,l of
2 mm dNTP mix, 20 pmol of oligonucleotides and 2 U of
Taq polymerase (Promega, USA) to give a final reaction
volume of 50 jil. The oligonucleotide sequences were as
follows: 5'-GACCCGGTGCCTCAGGA-3' corresponding to
nucleotides 142-158 and 5'-ATGGTCACGGTCTGCCA-3'
complementary to nucleotides 524-508 of the cDNA
encoding the human bax gene (Oltvai et al., 1993) or: 5'-
TTGGACAATGGACTGGTTGA-3' corresponding to nu-
cleotides 96-115 and 5'-GTAGAGTGGATGGTCAGTG-3'
complementary to nucleotides 860-842 of the cDNA
encoding the human bcl-x gene (Boise et al., 1993).
Amplification for both sets of primers was performed as
follows: (1) denaturation at 95°C for 2 min; (2) annealing at
60°C for 1 min; (3) extension at 720C for 1 min. Steps 1-3
were repeated 36 times with the exception that the final cycle
extension was for 10 min at 72°C.
The amplification mixture was electrophoresed on a 1.4%
agarose gel in the presence of ethidium bromide. The sizes of
the amplification products were 382 bp (bax), 764 bp (bcl-x,)
and 576 bp (bcl-x,). The amplification products, detected by
ultraviolet transillumination, were excised and 32p labelled
using an oligolabelling kit (Amersham International).
RNA preparation and Northern blot analyses
Cells in logarithmic phase of growth were collected by
centrifugation at 300 g for 10 min and suspended in 100 jl of
medium. A solution containing 6.0 M guanidine hydrochlor-
ide and 0.2 M sodium acetate (pH 5.5) was added to the cells
(20 ml per 5 x 107 cells) and RNA was precipitated by the
addition of a half volume of 95% ethanol followed by
incubation at -20°C overnight. The pelleted precipitate was
dissolved in a solution containing 7.0 M urea, 0.35 M sodium
chloride, 50 mM Tris pH 7.5, 1 mM EDTA and 0.2% sodium
dodecyl sulphate (SDS) and was extracted once with phenol-
chloroform. RNA was precipitated from the aqueous phase
using two volumes of ethanol, washed with 70% ethanol, air
dried and dissolved in sterile, double distilled water. Human
brain and lung mRNA was obtained from Cambridge
Bioscience, Cambridge, UK.
Total RNA (10 jug) in 10 mM sodium phosphate buffer
(pH 7.0) was denatured in 1.0 M glyoxal for 1 h at 50°C. The
RNA was electrophoresed in a 1.4% agarose gel in 10 mM
sodium phosphate buffer and was transferred by Northern
blotting to nylon filters. After treatment for 2 min with
ultraviolet light, the nylon filters were baked at 800C for 2 h
before hybridisation to oligolabelled cDNA probes. For all
Northern blot analyses, filters were probed with a mouse fi-
actin probe (PRT3) (kindly donated by Dr John Rogers,
Laboratory of Molecular Biology, Cambridge, UK) to
confirm approximately equal loading of RNA in all tracks.
Preparation ofmicrosomal membranes and immunodetection of
bcl-2
Crude membranes were prepared as described previously with
minor modifications (Reeve et al., 1993). Briefly, cells were
removed from tissue culture flasks using a cell-scraper and
were centrifuged at 300 xg for 4 min. The pellet was
resuspended in ice-cold lysis buffer consisting of 10 mM
Tris-HCl buffer (pH 7.4) containing 4 ,ug ml-' aprotinin,
4 jig ml-' leupeptin and 0.1 mM phenylmethylsulphonyl
fluoride, and homogenised by passage through a 26 gauge
syringe needle. The suspension was centrifuged at 450 xg for
10 min and the resulting supernatant further centrifuged at
50 000 xg for 1 h. The pellet was then resuspended in lysis
buffer to a final protein concentration of approximately
5 mg ml-' and stored at - 700C until assay.
Membrane proteins (100 jig) were electrophoresed on a
12.5% SDS-polyacrylamide gel under non-reducing condi-
tions. Proteins were transferred to cellulose nitrate paper as
described elsewhere (Reeve et al., 1993). After transfer,
additional protein binding sites on the nitrocellulose paper
were blocked by incubation overnight in 5 mM EDTA, 0.25%
gelatine, 0.01 M sodium azide, 0.15 M sodium chloride,
0.05 M Tris base and Nonidet P-40 (NGA buffer). Thepaper was then incubated overnight at 4°C with mouse
monoclonal antibody directed against Bcl-2 (Dako, High
Wycombe, UK) at a concentration of 10 4ug ml-' in NGA
buffer. After washing, affinity-purified 125I-labelled sheep anti-
mouse Ig F(ab')2 fragment (Amersham, Aylesbury, UK) was
used to visualise primary antibody binding.
Results
Bcl-2 gene expression in lung tumour cell lines
Northern blot analysis of bcl-2 gene expression in a panel of
SCLC cell lines derived from untreated and treated patients is
shown in Figure la. It can be seen that the bcl-2 cDNA
probe detected a 8.5 kb transcript in all SCLC cell lines
examined with the exception of COR-L279. Two smaller
transcripts of 6.0 kb and 3.5 kb were also consistently
detected in COR-L311, and the significance of this
observation is currently under investigation. It can be seen
that all SCLC cell lines examined hyperexpressed the bcl-2
gene as compared with normal adult human brain and lung.
COR-L42, -L88, -L316 and -L32 levels ofbcl-2 expression are
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similar to that observed in DoHH2, a B-cell lymphoma cell
line shown to hyperexpress bcl-2 (Cotter et al., 1994). No
difference was observed between the level of bcl-2 gene
expression in COR-L24, a tumour cell line derived from a
SCLC patient before treatment, and that in COR-L103
derived from a tumour in the same patient upon relapse after
a complete response to chemotherapy.
In contrast to the frequent expression of bcl-2 gene in
SCLC cell lines, it can be seen from Figure lb that only two
offive non-small-cell lung cancer cell lines hyperexpressed the
bcl-2 gene. The level of expression observed in the cell line
BEN was comparable with that observed in the follicular
lymphoma cell line.
Figure Ic shows bcl-2 protein expression in SCLC and
NSCLC cell lines with high, low or intermediate levels of
bcl-2 gene expression as determined by Northern blot
analysis. It can be seen by comparison with Figure la and
lb that the levels of mRNA and protein expression in the
different cell lines generally correlate well. However, the
relative expression of bcl-2 mRNA in COR-L24 and COR-
L51 does not appear to accord with that of bcl-2 protein in
these two cell lines.
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Figure 1 Bcl-2 expression in lung tumour cell lines. (a) Northern blot analysis of bcl-2 and actin expression in SCLC cell lines
derived from untreated patients and from patients treated with chemotherapy. (b) Northern blot analysis of bcl-2 and actin
expression in NSCLC cell lines. (c) Western immunoblot analysis of Bcl-2 protein expression in crude membrane preparations from
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Bcl-x gene expression in lung tumour cells
The majority of SCLC lines (Figure 2a) and all NSCLC cell
lines examined (Figure 2b) hyperexpressed the 2.7 kb bcl-x
gene transcript as compared with normal adult brain and
lung. The bcl-x probe also hybridised to a 3.1 kb transcript in
the majority of cell lines. The bcl-2-negative SCLC cell line
COR-L279 showed a level of bcl-x expression similar to that
seen in normal lung (Figure 2a). No relationship existed
between bcl-2 and bcl-x gene expression. RT-PCR was used
to determine which forms of bcl-x mRNA are expressed by
lung tumour cells as previously described (Boise et al., 1993).
It can be seen from Figure 2c that all lung lines examined
expressed predominantly the 780 bp bcl-x, mRNA. A much
fainter 590 bp bcl-x, mRNA species is also present in all of
the lines. As previously reported, the 780 bp bcl-xl transcript
was predominantly detected in human brain.
Bax gene expression in lung tumour cell lines
The bax cDNA probe, generated by RT-PCR, detected
1.5 kb and 1.0 kb transcripts in human adult lung and in the
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panel of SCLC (Figure 3a) and NSCLC (Figure 3b) cell lines
studied. In human brain, a prominent 1.5 kb transcript was
similarly detected but, in contrast to lung and tumour, the
smaller transcript existed as a well-defined doublet.
It can be seen that the bax gene is hyperexpressed in the
majority of lung tumour lines examined compared with
normal human lung and, to a lesser extent, with human
brain. All SCLC and NSCLC cell lines studied showed bax
gene expression and, unlike bcl-2 expression, a uniform level
of expression was observed in the majority of lung tumour
cell lines examined. However, relatively lower levels of bax
gene expression were detected in COR-L32 and in NCI-H69.
No relationship existed between the levels of bcl-2 and bax
gene expression.
Bcl-2, bax and bcl-x gene expression in drug-sensitive and -
resistant SCLC and NSCLC cells
Figure 4 shows Northern blot analysis of bcl-2 gene
expression in NCI-H69 and in its multidrug-resistant
variants (LX4, LX1O). No consistent quantitative change in
bcl-2 gene expression was observed in LX4 and LXIO
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Figure 2 Bcl-x gene expression in lung tumour cell lines. (a) Northern blot analysis of bcl-x and actin expression in SCLC cell lines.
(b) Northern blot analysis of bcl-x and actin expression in NSCLC cell lines. (c) RT-PCR analysis of the expression of bcl-x1 and
bcl-xs mRNAs expressed in SCLC cell lines, brain and NSCLC cell lines.
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Figure 3 Northern blot analysis of bax gene expression in SCLC cell lines (a) and in NSCLC cell lines (b). The same filters probed
with an actin cDNA are also shown.
-Actin
Figure 4 Northern blot analysis of bcl-2 gene expression in
multidrug-resistant SCLC and NSCLC cell lines. The lower panel
shows the same filter hybridised to an actin cDNA probe and
confirms the presence of mRNA in all lanes.
compared with the parental line. Similarly, no increase in bcl-
2 gene expression was observed in multidrug-resistant
variants of MOR/P and COR-L23/P. Western immunoblot
analysis also showed no increase in bcl-2 expression
associated with multidrug resistance (data not shown).
Northern blot analysis of bcl-x and bax gene expression
showed no consistent difference in the levels of bcl-x and bax
gene expression between drug-sensitive and drug-resistant
SCLC and NSCLC cell lines (data not shown).
Relationship between bcl-2, bax and p53 gene expression in
lung tumour cell lines
Figure 5 shows bcl-2, p53 and bax gene expression in a panel
of SCLC cell lines. COR-L47, COR-L316 and NCI-H69
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Figure 5 Relationship between bcl-2, p53 and bax gene
expression in SCLC cell lines as determined by Northern blot
analysis. The filter was sequentially probed with bcl-2, p53 and
bax cDNA probes. The lower panel shows the same filter
hybridised to an actin cDNA probe.
showed no detectable p53 transcript when total RNA was
used for analysis. However, a very low level of p53 gene
expression was detected in these cell lines when mRNA was
analysed (data not shown). The remaining cell lines showed
varying levels of p53 gene expression and no relationship
between the levels of p53, bcl-2 and bax gene expression was
evident. Similarly, no relationship between the expression of
these genes was observed in the NSCLC cell lines examined
(data not shown). Table I summarises the data for bcl-2, bcl-
x, bax and p53 gene expression and also gives the p53
genotype of the lung tumour cell lines examined.
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Table I Summary of bcl-2, bcl-x, bax and p53 expression in lung tumour cell lines
Gene
bcl-2 bcl-x bax p53
Cell line mRNAa Proteina mRNAa mRNAa mRNAa Genotypeb
SCLC
L32 2+ ND +/- + ND m*
L42 3+ 3+ 3+ 3+ + m
L47 1+ 1+ 3+ 2+ +/- -
L96C 1+ ND 3 + 3 + ND m*
L279 - - 1+ 2+ 3+ m*
L24 2+ 2+ 3+ 3+ 2+ m (het)
L103 2+ ND 3+ 2+ 2+ m (het)
L51 2+ 1+ 3+ 2+ 2+ m
L88 3+ 3+ 3+ 3+ 2+ m
L266 1+ ND 2+ 2+ m
L311 1+ 2+ 2+ 2+ +/- -
L316 3+ ND 2+ 2+ - m
L321 3+ 3+ 2+ 2+ 2+ m
H69/P 1+ ND 2+ 1+ +/ m
NSCLC
L23/P - 3+ 3+ 2+ m
MOR/P 1+ 1+ 2+ 3+ +/- m
L105 - 3+ 3+ 2+ -
LUDLU-1 - ND 3 + 2+ m
BEN 3+ 2+ 2+ 3+ 2+ m
aFor mRNA and protein expression: -, not detected; 1 +, weak expression; 2+, moderate expression; 3+, strong
expression; ND, not done.
Data generously provided by Dr PH Rabbitts. m*, silent mutation; m, mutation detected in exons 4-8; -, no
mutation detected in exons 4-8; m(het), heterozygous mutation.
Discussion
During the course of these studies Igegaki et al. (1994)
reported expression of the bcl-2 gene in five of six SCLC cell
lines studied and, more recently, bcl-2 expression has been
detected in both SCLC and NSCLC tumour biopsy speci-
mens (Ben-Ezra et al., 1994; Pezzella et al., 1993). Such
studies have led to the suggestion that bcl-2 oncoprotein
could play a role in the pathogenesis and therapeutic
responsiveness of lung cancer and that its expression in
tumours may be of prognostic significance. However, it is
becoming increasingly clear that the regulation of cell
survival/cell death involves a dynamic interplay between
death-repressor proteins, such as bcl-2 and bcl-xl, and death-
accelerator proteins, such as bax and bcl-x,. Thus, the relative
expression of death-suppressor and death-promoter genes
may be more predictive ofcellular susceptibility to cell death,
either during tumorigenesis or during cytotoxic therapy. The
findings of the present study demonstrate that multiple
apoptosis-regulatory genes are expressed by human lung
tumour cells and that the pattern of expression is largely
dependent on histological type. SCLC cells typically express
bcl-2, bcl and bax, whereas in NSCLC bcl-2 has a more
restricted distribution, with most lines expressing only bcl-2
and bax. The study shows that all lung tumour cell lines
examined preferentially express bcl-xl, the splice variant form
of bcl-x mRNA that inhibits apoptosis upon growth factor
withdrawal. Thus, SCLC cells express both bcl-2 and bcl-x,
and, presumably, are able to circumvent apoptosis in
response to certain death stimuli by invoking the survival
pathways effected by these two proteins. In contrast, most
NSCLC cell lines fail to express detectable bcl-2 and
preseumably bcl-x, is the major apoptosis-repressor protein
in these cells. These findings may have implications for
therapeutic strategies that target genes involved in the control
of apoptosis and, at present, suggest that whereas multiple
agents may be required to ablate survival pathways in SCLC,
a single agent directed against bcl-x, may be sufficient to elicit
apoptosis in the majority ofNSCLC. However, a larger study
including tumour biopsy material and a larger panel of
NSCLC cell lines is needed to test this hypothesis further.
Bcl-2 and bcl-x hyperexpression was observed in SCLC cell
lines derived both from patients who had received
chemotherapy before tumour biopsy collection and from
untreated patients, suggesting that the high level of
expression of these genes is a phenotypic property of this
tumour type that is not treatment related.
The molecular mechanisms underlying the hyperexpression
of the bcl-2 gene in SCLC and NSCLC cells remain
unknown. We have found no evidence for bcl-2 gene
amplification, or for gross alterations in bcl-2 gene structure
in SCLC and NSCLC cells, including t(14:18) translocations
responsible for the hyperexpression of bcl-2 in human
follicular lymphomas (data not shown). In the present
study, no reciprocal relationship between the level of mutant
p53 gene expression and bcl-2 gene expression was observed
in the lung tumour cell lines examined. This finding does not
accord with a recent report by Haldar et al. (1994) describing
down-regulation ofbcl-2 by mutant p53 in breast cancer cells.
In the latter study, high levels of mutant p53 mRNA and
protein were associated with low levels of bcl-2 gene
expression and vice versa. Most of the lung tumour cell
lines used in the present study have one or more mutations in
exons 4-8 of the p53 gene (see Table I), and several show
strong p53 immunostaining typical of mutant p53 (PH
Rabbits, personal communication and J Xiong, unpublished
results). Bcl-2 hyperexpression occurred in SCLC and
NSCLC cell lines showing both low (e.g.-L316, MOR) and
high levels (e.g.-L88, BEN) of mutant p53 gene expression
and protein production, indicating in the latter cell lines a
failure of mutant p53 protein to down-regulate bcl-2 gene
expression. The discrepancy between the findings in lung and
breast carcinomas cannot be attributed to differences in the
nature of the p53 mutations since several of the mutations
associated with bcl-2 down-regulation in breast cancer cells
were also present in the lung tumour cell lines examined.
Interestingly, it has been suggested that the magnitude of
wild-type p53 suppression of bcl-2 expression may be tissue
specific (Miyashita et al., 1994b). Thus, the apparent
difference in the suppressive effect of mutant p53 on bcl-2
expression seen in breast and lung tumour cells may reflect
such tissue-specific effects and/or the existence of other
unidentified factors which influence the regulation of the
bcl-2 gene by p53. Notwithstanding the findings in breast
tumour cells, it may be that the hyperexpression of bcl-2 in
lung tumours reflects p53 gene inactivation in these cells, asExpression of apoptosis-regulatory genes in lung tumour cells
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has been suggested previously (Miyashita et al., 1994a).
However, the bcl-2-negative SCLC cell line bcl-2-negative
NSCLC cell line LUDLU-1 express mutant and not wild-type
p53, challenging a simple relationship between p53 inactiva-
tion and bcl-2 hyperexpression in lung tumour cells.
Studies in p53 knock-out mice have demonstrated that p53
increases bax expression and, on the basis of this finding, it
has been suggested that p53 loss in human tumours will be
associated with decreased bax expression (Miyashita et al.,
1994a). The findings of the present study show that p53
mutation is not associated with loss of bax expression.
Indeed, the majority of lung tumour cell lines hyperexpressed
bax compared with normal lung and brain. In marked
contrast to the expression of bcl-2, which is considerably
greater in SCLC than in the majority of NSCLC cells, no
difference in the levels of bax gene expression in SCLC and
NSCLC cell lines was observed. As it has been suggested
previously that the ratio of bcl-2 to bax protein controls the
relative susceptibility of certain cells to death stimuli (Oltvai
et al., 1993), the observed differences in the relative levels of
bcl-2 and bax gene expression in SCLC and NSCLC cells
may indicate differences in their susceptibility to apoptotic
death.
Bcl-2 gene transfection studies in various neoplastic
lymphoid cell lines and in human neuroblastoma cell lines
have shown that elevation of the level of bcl-2 protein
markedly increased resistance to a variety of chemother-
apeutic drugs (Ohmori et al., 1993; Miyashita and Reed,
1992; Fisher et al., 1993; Kamesaki et al., 1993; Dole et al.,
1994; Miyashita and Reed, 1993). Conversely, bcl-2 antisense
studies in which levels of bcl-2 were reduced significantly
increased cellular sensitivity to these drugs (Kitada et al.,
1994). Such findings highlight the ability of bcl-2 to provide
a mechanism for tumour cells to survive the cytotoxic effects
of chemotherapy. In the present study, no change in the
levels of bcl-2, bcl-x or bax gene expression were observed
between the SCLC cell line COR-L24 derived from an
untreated tumour that responded completely to subsequent
chemotherapy and the cell line COR-103 derived from a
recurrent tumour in this patient. Similarly, no increases in
either bcl-2 or bcl-x gene expression were observed in the P-
glycoprotein-positive multidrug-resistant SCLC cell lines or
the P-glycoprotein-negative drug-resistant NSCLC lung
tumour cell lines. As no resistance-related decrease in bax
expression was observed in these cells, it is unlikely that bel-
2, bcl-x and bax are mechanistically involved in the
acquisition of in vitro multidrug resistance. However, it has
been reported recently that transfection of the bcl-2 gene
into a SCLC non-expressor resulted in increased resistance
to chemotherapeutic agents including doxorubicin and
mitomycin C (Ohmori et al., 1993). Such findings suggest
that changes in the relative expression of apoptosis
regulatory genes may be a major determinant of drug
sensitivity in lung tumour cells and indicate a therapeutic
potential for treatment strategies that modulate the
expression of the genes.
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